Effects of Niacin on Glucose Control in Patients With Dyslipidemia

Slides:

Advertisements

Similar presentations

Clinical Pharmacology, Uses, and Adverse Reactions of Iodinated Contrast Agents: A Primer for the Non-radiologist Jeffrey J. Pasternak, MD, Eric E. Williamson,

Advertisements

My Treatment Approach to Hairy Cell Leukemia Rahul R. Naik, MD, Alan Saven, MD Mayo Clinic Proceedings Volume 87, Issue 1, Pages (January 2012) DOI:

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Nonfasting Glucose, Ischemic Heart Disease, and.

Celebrating the Sesquicentennial of Mayo Clinic: 150 Years of Advances in Medical Practice, Education, Research, and Professionalism William L. Lanier,

Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus

The Epidemic of the 20th Century: Coronary Heart Disease

From: Pharmacologic Therapy for Type 2 Diabetes Mellitus

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Copyright © 2007 American Medical Association. All rights reserved.

Copyright © 2009 American Medical Association. All rights reserved.

Managing Cancer Pain: Basic Principles and Invasive Treatments

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

David P. Steensma, MD, Ayalew Tefferi, MD Mayo Clinic Proceedings

J. Eric Ahlskog, PhD, MD Mayo Clinic Proceedings

Family-Based Therapy for Adolescents With Anorexia Nervosa

James H. O’Keefe, MD, Salman K. Bhatti, MD, Ata Bajwa, MD, James J

Evaluation of Proteinuria

Robert M. Jacobson, MD, George J. Isham, MD, MS, Lila J

Jean L. Chan, MD, Martin J. Abrahamson, MD Mayo Clinic Proceedings

Brian Radbill, MD, Barbara Murphy, MD, Derek LeRoith, MD, PhD

Glycemic Control, Mealtime Glucose Excursions, and Diabetic Complications in Type 2 Diabetes Mellitus P.J. Palumbo, MD Mayo Clinic Proceedings Volume.

Omega-3 Fatty Acids for Cardioprotection

William L. Lanier, MD Mayo Clinic Proceedings

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

The Impact of Migraine and the Effect of Migraine Treatment on Workplace Productivity in the United States and Suggestions for Future Research Wayne.

Treatment of Alcohol Withdrawal in Hospitalized Patients

Athena Philis-Tsimikas, MD The American Journal of Medicine

Sumana Narasimhan, MD, Ruth S. Weinstock, MD, PhD

Can Vitamin D Deficiency Break Your Heart?

Step Care Therapy for Hypertension in Diabetic Patients

Wisit Cheungpasitporn, MD, Charat Thongprayoon, MD, Qi Qian, MD

Peripheral Arterial Disease: Diagnosis and Management

George Dailey, MD Mayo Clinic Proceedings

Statins in the Treatment of Dyslipidemia in the Presence of Elevated Liver Aminotransferase Levels: A Therapeutic Dilemma Rossana M. Calderon, MD, Luigi.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Palliative Care and Hospice Programs

Cannabinoid Hyperemesis: A Case Series of 98 Patients

The Epidemic of the 20th Century: Coronary Heart Disease

Gerry H. Tan, M.D., Roger L. Nelson, M.D. Mayo Clinic Proceedings

Body Composition and Heart Failure Prevalence and Prognosis: Getting to the Fat of the Matter in the “Obesity Paradox” Carl J. Lavie, MD, Richard V.

Exercise-Based Cardiac Rehabilitation and Improvements in Cardiorespiratory Fitness: Implications Regarding Patient Benefit Barry A. Franklin, PhD Mayo.

Contemporary Evidence-Based Guidelines

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

MIGUEL A. VALDOVINOS, M. D. , MICHAEL CAMILLERI, M. D. , BRUCE R

On Statin Treatment to Prevent Sepsis in Dialysis Patients

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Peripartum Cardiomyopathy Presenting as an Acute Myocardial Infarction

Risks for Cardiovascular and Cardiac Deaths in Nonobese Patients With Diabetes and Coronary Heart Disease Tetsuro Tsujimoto, MD, PhD, Hiroshi Kajio,

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Osteoporosis Associated With Megestrol Acetate

Diabetic Mastopathy Mayo Clinic Proceedings

Adjunctive Therapies in the Treatment of Acute Coronary Syndromes

Postoperative Trouble

Celebrating the Sesquicentennial of Mayo Clinic: 150 Years of Advances in Medical Practice, Education, Research, and Professionalism William L. Lanier,

Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus James H. O'Keefe, MD, Mohammad Abuannadi,

Medical Treatment of Overactive Bladder: In Response

Coronary Revascularization on Balance: Robert L. Frye Lecture

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Preoperative Smoking Cessation: The Role of the Primary Care Provider

How Good Intentions Contributed to Bad Outcomes: The Opioid Crisis

David E. Winchester, MD, David C. Wymer, MD, Roger Y

Is There an “Asymptote of Gain” Beyond Which Further Increases in Cardiorespiratory Fitness Convey No Additional Benefits on Mortality and Atrial Fibrillation?

Autonomic Tone and Benefits of Cardiac Rehabilitation Programs

Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both Conditions Ajay Nehra, MD

Guy S. Reeder, M.D., Raymond J. Gibbons, M.D. Mayo Clinic Proceedings

Wisit Cheungpasitporn, MD, Charat Thongprayoon, MD, Qi Qian, MD

Managing Cancer Pain: Basic Principles and Invasive Treatments

β-Blocker Use for the Stages of Heart Failure

Presentation transcript:

Effects of Niacin on Glucose Control in Patients With Dyslipidemia Ronald B. Goldberg, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings Volume 83, Issue 4, Pages 470-478 (April 2008) DOI: 10.4065/83.4.470 Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 1 Effects of niacin and placebo on fasting glucose over time in patients with or without diabetes mellitus. Between baseline and week 0, patients' regimens were titrated to 1 g/d. From week 0 to week 18, regimens were titrated from 1 g/d to 3 g/d. SI conversion factor: To convert glucose values to mmol/L, multiply by 0.0555. From JAMA,19 Copyright © 2000, with permission from the American Medical Association. All rights reserved. Mayo Clinic Proceedings 2008 83, 470-478DOI: (10.4065/83.4.470) Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 2 Effects of simvastatin-niacin (SN) and placebo on fasting glucose (top panels) and insulin (bottom panels) levels over time in patients with or without diabetes mellitus (DM). Post = up to 3 years. SI conversion factor: To convert glucose values to mmol/L, multiply by 0.0555. From Am J Cardiol,21 Copyright © 2004, with permission from Elsevier. Mayo Clinic Proceedings 2008 83, 470-478DOI: (10.4065/83.4.470) Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 3 Effects of niacin and placebo on postprandial glucose (mean 1-hour plasma glucose after a glucose load ≥180 mg/dL) (to convert to mmol/L, multiply by 0.0555). Closeout visit (CV) 2 was 4 months after CV 1. Only patients completing CV 2 were included. Data from reference 24. Mayo Clinic Proceedings 2008 83, 470-478DOI: (10.4065/83.4.470) Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 4 Effects of niacin and placebo on 6-year rate of myocardial infarction (MI) (A), 6-year rate of coronary artery disease (CAD) death or MI (B), and 15-year all-cause mortality rates (C) according to baseline levels of fasting glucose (FG). HR = hazard ratio. Z values based on test for homogeneity of treatment effect by FG were -0.44 for MI, 0.47 for CAD death or MI, and -0.63 for all-cause mortality, with values between -1.96 and +1.96 indicating homogeneity (no statistical differences) in HRs across FG levels. SI conversion factor: To convert glucose values to mmol/L, multiply by 0.0555. From Am J Cardiol,24 Copyright © 2005, with permission from Elsevier. Mayo Clinic Proceedings 2008 83, 470-478DOI: (10.4065/83.4.470) Copyright © 2008 Mayo Foundation for Medical Education and Research Terms and Conditions